Jubilant Pharmova Recommends 500% Dividend, Approves FY26 Audited Results
Jubilant Pharmova's Board approved audited financial results for FY26. A final dividend of 500% (₹5 per share) was recommended. July 24, 2026, is the record date for dividend payment.
The recommendation of a substantial dividend and approval of annual results are material events for the company and its investors, impacting investor sentiment and potentially share price.
The company announced the approval of audited financial results and recommended a significant final dividend, which is positive for shareholders.
Jubilant Pharmova Limited announced the outcome of its Board Meeting held on May 22, 2026. The Board approved the audited financial results, both standalone and consolidated, for the quarter and financial year ended March 31, 2026. The auditors have issued an unmodified opinion on these results.
Furthermore, the Board recommended a final dividend of 500%, which translates to ₹5 per equity share of ₹1 face value, for the financial year ended March 31, 2026. This dividend, if approved by the shareholders, will be paid within 30 days of the Annual General Meeting.
The company has fixed Friday, July 24, 2026, as the record date for the purpose of this final dividend payment.
What to do with a filing like this
Jubilant Pharmova Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Pharmova Limited. Read the original for the full detail.